RYTM
Rhythm Pharmaceuticals, Inc.
$109.69
-0.27 (-0.25%)
At close · Jul 15
Market Cap
$7.48B
Shares
68,532,607
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$189.76M
+45.8%
FY2025
Net Income
-$196.54M
+24.6%
FY2025
Gross Margin
89.73%
0pp
FY2025
Operating Margin
-101.19%
+102.8pp
FY2025
Diluted EPS
-$3.11
+28.3%
FY2025
Operating Cash Flow
-$115.68M
-1.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $217.17M | $189.76M | $130.13M | $77.43M | $23.64M | $3.15M | $0 | $0 | $0 | $0 | |
| $23M | $19.49M | $13.37M | $9.3M | $2.13M | $599K | — | — | — | — | |
| $194.16M | $170.27M | $116.76M | $68.13M | $21.51M | $2.56M | — | — | — | — | |
| — | 89.73% | 89.73% | 87.99% | 90.98% | 81.01% | — | — | — | — | |
| $172.09M | $167.34M | $237.96M | $134.95M | $108.63M | $104.13M | $90.45M | $109.45M | $50.34M | $22.89M | |
| $219.45M | $194.94M | $144.3M | $117.53M | $92.03M | $68.49M | $46.13M | $36.55M | $28.08M | $9.52M | |
| — | — | — | $855K | $774K | $342K | — | — | — | — | |
| — | $500K | $710K | $903K | $896K | $816K | $690K | $834K | $442K | $223K | |
| — | — | — | — | — | — | $136.58M | $146M | $78.42M | $32.41M | |
| $414.54M | $381.77M | $395.63M | $261.79M | $202.8M | $173.21M | — | — | — | — | |
| -$197.37M | -$192.02M | -$265.5M | -$184.36M | -$179.16M | -$170.06M | -$136.58M | -$146M | -$78.42M | -$32.41M | |
| — | -101.19% | -204.04% | -238.1% | -757.92% | -5391.85% | — | — | — | — | |
| — | -$191.52M | -$264.79M | -$183.45M | -$178.26M | -$169.24M | -$135.89M | -$145.17M | -$77.98M | -$32.19M | |
| $19.76M | $20.58M | $20.6M | $13.89M | $5.2M | — | — | — | — | — | |
| — | — | — | — | — | $447K | $2.58M | $5.27M | $4.35M | $566K | |
| -$4.35M | -$4.03M | $5.25M | $243K | -$1.96M | $100.45M | $2.58M | $5.27M | $4.35M | -$1.3M | |
| -$201.72M | -$196.04M | -$260.26M | -$184.11M | — | — | — | — | — | — | |
| $962K | $497K | $346K | $564K | — | — | — | — | — | — | |
| -$202.68M | -$196.54M | -$260.6M | -$184.68M | -$181.12M | -$69.61M | -$134M | -$140.73M | -$74.06M | -$33.71M | |
| — | -103.57% | -200.27% | -238.52% | -766.22% | -2207.1% | — | — | — | — | |
| -$207.84M | -$201.92M | -$264.57M | — | — | — | -$134M | -$140.73M | -$74.06M | -$37.58M | |
| -$206.24M | -$202.67M | -$264.75M | -$184.45M | -$181.21M | -$69.61M | -$133.95M | — | — | — | |
| USD/shares | — | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 | — | — | — | — |
| USD/shares | — | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 | — | — | — | — |
| shares | — | 64.98M | 61M | 57.67M | 52.12M | 49.6M | 44.13M | 36.42M | 31M | 13.27M |
| shares | — | 64.98M | 61M | 57.67M | 52.12M | 49.6M | 44.13M | 36.42M | 31M | 13.27M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
34.68×
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 25.59×
P/E (TTM)
—
Biotechnology median 7.55×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Single Reportable Segment | $189,757,000 | $130,126,000 | $77,428,000 | $23,638,000 |
By Geography (USD)
| Component | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| United States | $96,108,000 | $62,425,000 | $21,078,000 | $3,154,000 |
| Non Us | $34,018,000 | $15,003,000 | $2,560,000 | — |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Product | $194,771,000 | $130,126,000 | $77,428,000 | $16,884,000 | $3,154,000 |
| License | -$5,014,000 | $0 | $0 | $6,754,000 | — |
Key facts
CIK
1649904
CUSIP
76243J105
13F (30d)
20 filings
19 filers
Visit website
Investor relations